Pharsight, Critical Path Institute renal news

Pharsight and the institute's Polycystic Kidney Disease (PKD) Consortium will use clinical data collected from PKD patients through patient registries and clinical trials to develop quantitative disease progression models in patients with Autosomal Dominant PKD (ADPKD). The models will evaluate the relationship between the imaging biomarker total kidney volume (TKV) and the known complications of ADPKD, which include rate of loss of kidney function, the development of end-stage renal disease (ESRD) and mortality. Pharsight said analyses of the models will be used to support the regulatory qualification of TKV as an accepted endpoint to assess the progression of ADPKD in clinical trials for treatments for the disease. ...